These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 26319061)

  • 21. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
    Vesikari T; Baer M; Willems P
    Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence of IgG antibody against measles, mumps and rubella in bangladeshi children: a pilot study to evaluate the need for integrated vaccination strategy.
    Sultana R; Rahman MM; Hassan Z; Hassan MS
    Scand J Immunol; 2006 Dec; 64(6):684-9. PubMed ID: 17083626
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Seroprevalence and Determinants Associated with Mumps Antibodies after 20 Years of MMR Vaccination in Urban Area of Shanghai, China.
    Pang H; Zhou Y; Zhao W; Jiang Q
    Int J Environ Res Public Health; 2018 Sep; 15(10):. PubMed ID: 30249033
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Measles Virus Neutralizing Antibody Response, Cell-Mediated Immunity, and Immunoglobulin G Antibody Avidity Before and After Receipt of a Third Dose of Measles, Mumps, and Rubella Vaccine in Young Adults.
    Fiebelkorn AP; Coleman LA; Belongia EA; Freeman SK; York D; Bi D; Kulkarni A; Audet S; Mercader S; McGrew M; Hickman CJ; Bellini WJ; Shivakoti R; Griffin DE; Beeler J
    J Infect Dis; 2016 Apr; 213(7):1115-23. PubMed ID: 26597262
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term immunity to measles, mumps and rubella after MMR vaccination among children with bone marrow transplants.
    Spoulou V; Giannaki M; Vounatsou M; Bakoula C; Grafakos S
    Bone Marrow Transplant; 2004 Jun; 33(12):1187-90. PubMed ID: 15077129
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity and efficacy of Hoshino strain of mumps vaccine in Iran; two years study.
    Avijgan M; Hafizi M; Moghni M; Kheiri S; Esteghamati A; Sarikhani S
    East Afr J Public Health; 2011 Jun; 8(2):88-91. PubMed ID: 22066292
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Persistence of antibodies in 4-8 year old Austrian children after vaccination with hexavalent DTaP-HBV-IPV/Hib and MMR vaccines.
    Paulke-Korinek M; Fischmeister G; Grac A; Rendi-Wagner P; Kundi M; Mohsenzadeh-Rabbani A; Moritz K; Fenninger B; Jarisch R; Jasinska J; Holzmann H; Wiedermann U; Kollaritsch H
    Vaccine; 2011 Jul; 29(32):5130-6. PubMed ID: 21624412
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Humoral and cell-mediated immune responses to an early 2-dose measles vaccination regimen in the United States.
    Gans HA; Yasukawa LL; Alderson A; Rinki M; DeHovitz R; Beeler J; Audet S; Maldonado Y; Arvin AM
    J Infect Dis; 2004 Jul; 190(1):83-90. PubMed ID: 15195246
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age.
    Redd SC; King GE; Heath JL; Forghani B; Bellini WJ; Markowitz LE
    J Infect Dis; 2004 May; 189 Suppl 1():S116-22. PubMed ID: 15106100
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Waning antibody levels and avidity: implications for MMR vaccine-induced protection.
    Kontio M; Jokinen S; Paunio M; Peltola H; Davidkin I
    J Infect Dis; 2012 Nov; 206(10):1542-8. PubMed ID: 22966129
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative evaluation of measles, mumps & rubella vaccine at 9 & 15 months of age.
    Yadav S; Thukral R; Chakarvarti A
    Indian J Med Res; 2003 Nov; 118():183-6. PubMed ID: 14723482
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine.
    Gillet Y; Steri GC; Behre U; Arsène JP; Lanse X; Helm K; Esposito S; Meister N; Desole MG; Douha M; Willems P
    Vaccine; 2009 Jan; 27(3):446-53. PubMed ID: 19007835
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differences in persistence of measles, mumps, rubella, diphtheria and tetanus antibodies between children with rheumatic disease and healthy controls: a retrospective cross-sectional study.
    Heijstek MW; van Gageldonk PG; Berbers GA; Wulffraat NM
    Ann Rheum Dis; 2012 Jun; 71(6):948-54. PubMed ID: 22172491
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Response to third rubella vaccine dose.
    Siira L; Nøkleby H; Barlinn R; Riise ØR; Aaberge IS; Dudman SG
    Hum Vaccin Immunother; 2018; 14(10):2472-2477. PubMed ID: 29771601
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Could the MMR vaccine replace the measles vaccine at one year of age in Egypt?
    Abbassy AA; Barakat SS; Abd El Fattah MM; Said ZN; El Metwally HA
    East Mediterr Health J; 2009; 15(1):85-93. PubMed ID: 19469430
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased measles-mumps-rubella (MMR) vaccine uptake in the context of a targeted immunisation campaign during a measles outbreak in a vaccine-reluctant community in England.
    Le Menach A; Boxall N; Amirthalingam G; Maddock L; Balasegaram S; Mindlin M
    Vaccine; 2014 Feb; 32(10):1147-52. PubMed ID: 24440207
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Seroprevalence of measles antibody and its attributable factors in elementary students of routine 2-dose schedule era with vaccination record].
    Bae GR; Lim HS; Goh UY; Yang BG; Kim YT; Lee JK
    J Prev Med Public Health; 2005 Nov; 38(4):431-6. PubMed ID: 16358829
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rubella virus neutralizing antibody response after a third dose of measles-mumps-rubella vaccine in young adults.
    McLean HQ; Fiebelkorn AP; Ogee-Nwankwo A; Hao L; Coleman LA; Adebayo A; Icenogle JP
    Vaccine; 2018 Sep; 36(38):5732-5737. PubMed ID: 30107992
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development and Use of an Endpoint Titration Assay To Characterize Mumps IgG Avidity following Measles, Mumps, and Rubella Vaccination and Wild-Type Mumps Infection.
    Mercader S; McGrew M; Sowers SB; Williams NJ; Bellini WJ; Hickman CJ
    mSphere; 2018 Sep; 3(5):. PubMed ID: 30209129
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Application of a fast and cost-effective 'three-in-one' MMR ELISA as a tool for surveying anti-MMR humoral immunity: the Hungarian experience.
    Böröcz K; Csizmadia Z; Markovics Á; Farkas N; Najbauer J; Berki T; Németh P
    Epidemiol Infect; 2020 Feb; 148():e17. PubMed ID: 32014073
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.